Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.

Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Huang J, Martin DF, Jaffe GJ; Comparison of Age-related Macular Degeneration Treatments Trials Research Group..

Ophthalmology. 2016 Apr;123(4):865-75. doi: 10.1016/j.ophtha.2015.12.002. Epub 2016 Jan 9.

2.

Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.

Shah N, Maguire MG, Martin DF, Shaffer J, Ying GS, Grunwald JE, Toth CA, Jaffe GJ, Daniel E; Comparison of Age-related Macular Degeneration Treatments Trials Research Group..

Ophthalmology. 2016 Apr;123(4):858-64. doi: 10.1016/j.ophtha.2015.11.030. Epub 2016 Jan 8.

3.

Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

Daniel E, Shaffer J, Ying GS, Grunwald JE, Martin DF, Jaffe GJ, Maguire MG; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group..

Ophthalmology. 2016 Mar;123(3):609-16. doi: 10.1016/j.ophtha.2015.10.034. Epub 2015 Dec 8.

4.

Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials.

Willoughby AS, Ying GS, Toth CA, Maguire MG, Burns RE, Grunwald JE, Daniel E, Jaffe GJ; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group..

Ophthalmology. 2015 Sep;122(9):1846-53.e5. doi: 10.1016/j.ophtha.2015.05.042. Epub 2015 Jul 2.

5.

High soil and groundwater arsenic levels induce high body arsenic loads, health risk and potential anemia for inhabitants of northeastern Iran.

Taheri M, Mehrzad J, Mahmudy Gharaie MH, Afshari R, Dadsetan A, Hami S.

Environ Geochem Health. 2016 Apr;38(2):469-82. doi: 10.1007/s10653-015-9733-9. Epub 2015 Jun 23.

PMID:
26100324
6.

Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).

Altaweel MM, Daniel E, Martin DF, Mittra RA, Grunwald JE, Lai MM, Melamud A, Morse LS, Huang J, Ferris FL 3rd, Fine SL, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group.; Comparison of Age-related Macular Degeneration Treatments Trials CATT Research Group..

Ophthalmology. 2015 Feb;122(2):391-398.e5. doi: 10.1016/j.ophtha.2014.08.020. Epub 2014 Oct 11.

7.

Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials.

Folgar FA, Jaffe GJ, Ying GS, Maguire MG, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group..

Ophthalmology. 2014 Oct;121(10):1956-65. doi: 10.1016/j.ophtha.2014.04.020. Epub 2014 May 15.

8.

VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).

Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group..

JAMA Ophthalmol. 2014 May;132(5):521-7.

9.

Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.

Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS, Grunwald JE, Huang J; Comparison of Age-related Macular Degeneration Treatments Trials Research Group..

Ophthalmology. 2013 Sep;120(9):1860-70. doi: 10.1016/j.ophtha.2013.01.073. Epub 2013 May 1.

10.

Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT).

Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Callanan DG, Kim IK, Klein ML, Maguire MG, Martin DF; Comparison of AMD Treatments Trials Research Group..

Ophthalmology. 2013 Mar;120(3):593-9. doi: 10.1016/j.ophtha.2012.11.037. Epub 2013 Jan 18.

11.

Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.

Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, Daniel E, Klein M, Pieramici D, Wells J, Martin DF; Comparison of Age-related Macular Degeneration Treatments Trials Research Group..

Ophthalmology. 2013 Jan;120(1):122-9. doi: 10.1016/j.ophtha.2012.07.042. Epub 2012 Oct 6.

12.

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.

Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group., Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd.

Ophthalmology. 2012 Jul;119(7):1388-98. doi: 10.1016/j.ophtha.2012.03.053. Epub 2012 May 1.

13.

Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

CATT Research Group., Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ.

N Engl J Med. 2011 May 19;364(20):1897-908. doi: 10.1056/NEJMoa1102673. Epub 2011 Apr 28.

14.

Whispering gallery modes in standard optical fibres for fibre profiling measurements and sensing of unlabelled chemical species.

Boleininger A, Lake T, Hami S, Vallance C.

Sensors (Basel). 2010;10(3):1765-81. doi: 10.3390/s100301765. Epub 2010 Mar 3.

15.

Social impact of leishmaniasis, Afghanistan.

Reithinger R, Aadil K, Kolaczinski J, Mohsen M, Hami S.

Emerg Infect Dis. 2005 Apr;11(4):634-6. No abstract available.

16.

The structure of obsessionality among young adults.

Mathews CA, Jang KL, Hami S, Stein MB.

Depress Anxiety. 2004;20(2):77-85.

PMID:
15468097
17.

Cutaneous leishmaniasis, northern Afghanistan.

Reithinger R, Aadil K, Hami S, Kolaczinski J.

Emerg Infect Dis. 2004 May;10(5):966-7. No abstract available.

18.

Neuropsychological function in college students with and without posttraumatic stress disorder.

Twamley EW, Hami S, Stein MB.

Psychiatry Res. 2004 May 30;126(3):265-74.

19.

Sexual dysfunction in combat veterans with post-traumatic stress disorder.

Cosgrove DJ, Gordon Z, Bernie JE, Hami S, Montoya D, Stein MB, Monga M.

Urology. 2002 Nov;60(5):881-4.

PMID:
12429320
20.

Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study.

Stein MB, Sareen J, Hami S, Chao J.

Am J Psychiatry. 2001 Oct;158(10):1725-7.

PMID:
11579011

Supplemental Content

Loading ...
Support Center